Get started
Work

P1.11.32 Quality of Life Outcomes from the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK- Mutated NSCLC

Year: 2025
Type: article
DOI: 10.1016/j.jtho.2025.09.332
Authors: E.J. Kang, S. Park, T.M. Kim, J-Y. Han, G-W. Lee, B.Y. Shim, Y-G. Lee, S-W. Kim, I.H. Kim, S. Lee, Y.J. Kim, J.H. Park, S-G. Park, K.H. Lee, J.W. Kim, S-H. Shin, B-H.N. Nam, C-Y. Ock, J. Lee, H.A. Jung, J-M. Sun, S-H. Lee, J.S. Ahn, M-J. Ahn
Institutions: Korea University Guro Hospital, Samsung Medical Center, Chosun University Hospital, Sungkyunkwan University, Seoul National University Hospital, National Cancer Center, Gyeongsang National University, Gyeongsang National University Hospital, The Catholic University of Korea St. Vincent's Hospital, Kangbuk Samsung Hospital, Asan Medical Center, University of Ulsan, Inje University Haeundae Paik Hospital, Dong-A University, Seoul National University, Seoul National University Bundang Hospital, Konkuk University Medical Center, Chungbuk National University, Chungbuk National University Hospital, Korea University Anam Hospital, Kosin University Gospel Hospital, Lunit (South Korea)
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4415519195
FWCI:
Cites:
Cited by:
Related to: